Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

How to Use the Newly Authorized Oral Antiviral Agents for COVID-19

Hear expert insights on a stepwise approach to evaluate treatment candidacy for oral antiviral agents for COVID-19 and practical considerations for their use.
Kristen Marks, MD
Released: February 3, 2022

Information on this Educational Activity

Faculty

Kristen Marks, MD

Assistant Professor of Medicine
Division of Infectious Diseases
Weill Cornell Medicine
New York, New York

Kristen Marks, MD, has disclosed that she has received funds for research support paid to Weill Cornell Medicine from Gilead Sciences.

Program Medium

This program has been made available online.

Related Content

Prof. Sharon R. Lewin: expert insights on remdesivir for nonhospitalized adult and pediatric patients with COVID-19, from Clinical Care Options (CCO)

Sharon R. Lewin, AO, FRACP, PhD, FAHMS Released: June 7, 2022

Prof. Sharon R. Lewin discusses ivermectin and the evolution of monoclonal antibody treatments during omicron, from Clinical Care Options (CCO)

Sharon R. Lewin, AO, FRACP, PhD, FAHMS Released: June 7, 2022

Megan Coffee, MD, PhD, discusses the newest data on SARS-CoV-2 diagnostics from CROI 2022 and elsewhere, from Clinical Care Options (CCO)

Megan Coffee, MD, PhD (DPhil) Released: June 2, 2022

Frequently asked questions and answers: evolving data on COVID-19 epidemiology, prevention, and treatment, from Clinical Care Options (CCO)

Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Renslow Sherer, MD Released: June 1, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings